In music, the rest is part of the score. Leave it out and the melody collapses into noise. For years, oncologists treated adjuvant endocrine therapy like a passage you were never, ever allowed to stop playing - five to ten uninterrupted years of tamoxifen or an aromatase inhibitor, no breath marks, no fermatas. The POSITIVE trial asked a question that made a lot of us clutch our protocols: what if a young woman wants to put the instrument down for a couple of years to have a baby? Does the whole symphony fall apart?
The newly updated results say: the rest holds.
What POSITIVE Actually Did (And Why Single-Arm Trials Make Me Nervous)
POSITIVE enrolled 518 women under 42 with stage I-III hormone receptor-positive breast cancer who'd already taken 18 to 30 months of endocrine therapy and wanted to get pregnant. They paused treatment for up to two years to try, then - per protocol - resumed. No randomization. A single-arm study, which is the kind that keeps a trialist up at night, because without a control group you're basically singing a cappella and hoping you're on pitch.
The clever bit is how they found their pitch. Rather than shrug and say "looks fine to us," the investigators used a bootstrap-matching method to compare outcomes against women from the SOFT and TEXT trials as external controls - a real comparator built from real patients on continuous therapy (Francis et al., NEJM 2018, doi:10.1056/NEJMoa1803164). That is how you build an alibi for a single-arm design.
The Update: Longer Follow-Up, Same Reassuring Tune
The original 2023 readout, at a median 41 months, was encouraging but short (Partridge et al., NEJM 2023, doi:10.1056/NEJMoa2212856). And in hormone-positive disease, short follow-up is a trap, because this cancer is famous for showing up late - recurrences strolling in a decade after diagnosis like a guest who ignored the RSVP.
So here's the part that matters. At a median of 71 months now, the 5-year cumulative incidence of breast cancer-free interval events was 12.3% in POSITIVE versus 13.2% in the SOFT/TEXT controls. A difference of -0.9% (95% CI -4.2% to 2.6%). Distant recurrence events came in at 6.2% versus 8.3%. Translation for the bar, not the tumor board: pausing therapy to have a baby did not buy these women extra recurrences. The confidence intervals straddle zero, which is exactly what you want to see when the scary direction would be a positive number.
And the babies arrived. Of 497 women followed for non-disease outcomes, 76% had at least one documented pregnancy, 69% had at least one live birth, and 440 little humans entered the world. For a population repeatedly told that motherhood was off the table, that is a remarkable encore.
The Fertility-Preservation Footnote Worth Watching
One subgroup gave me pause. The 180 women (36%) who'd banked embryos or eggs before enrolling had a slightly higher 5-year event rate (14.0%) than those who didn't (11.5%). Before anyone blames the cryotank: this was unadjusted, and women who pursue fertility preservation may differ in ways that matter - age, stage, how badly the biology was misbehaving. It's a signal to interrogate, not a verdict. Confounding by indication is the oldest ghost in our house.
Why This Changes the Conversation
For decades the counseling script was grim arithmetic: your treatment versus your family. POSITIVE reframes it as a structured, time-limited pause within a plan, not an act of rebellion against one. This aligns with a growing pile of evidence that pregnancy after breast cancer does not worsen prognosis, even in BRCA carriers (Lambertini et al., J Clin Oncol 2021, doi:10.1200/JCO.21.00535).
The honest caveat, which the authors state plainly: keep following these women. Late recurrence is real, the curves aren't done, and a 5-year snapshot of a 15-year disease is a single movement, not the finale. But for now, the rest in the score looks safe to play. And somewhere, 440 kids have no idea their existence required a data monitoring committee to sleep soundly.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.
References
- Pagani O, Niman SM, Ruggeri M, et al. Updated Results of the POSITIVE Trial. Annals of Oncology. 2026. doi:10.1016/j.annonc.2026.05.699. PMID: 42214557.
- Partridge AH, Niman SM, Ruggeri M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med. 2023;388(18):1645-1656. doi:10.1056/NEJMoa2212856.
- Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (SOFT/TEXT). N Engl J Med. 2018;379:122-137. doi:10.1056/NEJMoa1803164.
- Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021;39(29):3293-3305. doi:10.1200/JCO.21.00535.